证券代码：301015 证券简称：百洋医药 公告编号：2026-003 债券代码：123194 债券简称：百洋转债 青岛百洋医药股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 二、担保进展情况 为满足日常经营资金需求，天津百洋向中国光大银行股份有限公司青岛分行（以 下简称"光大银行"）申请了综合授信额度，公司与光大银行签订了《最高额保证 合同》，为上述授信额度提供连带责任保证担保，公司对天津百洋担保的主债权最 高本金余额为 1,000 万元。 为满足日常经营资金需求，上海制药向南京银行股份有限公司上海分行（以下 简称"南京银行"）申请了综合授信额度，百洋制药与南京银行签订了《最高额保 证合同》，为上述授信额度提供连带责任保证担保，百洋制药对上海制药的担保债 权的最高本金余额为 3,000 万元。 本次担保事项在前述担保额度范围内，无需另行召开董事会及股东会审议。 本次担保前公司对天津百洋已提供且尚在担保期限内的担保余额为1,000万元； 本次担保后公司对天津百洋已提供且尚在担保期限内的担保余额为 1,000 万元， ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 19, 2026 [1] Core Insights - 2025 marked a significant year for Chinese innovative drugs going global, with a total transaction amount of $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs. The trend continues into 2026, with notable licensing agreements from companies like Yilian Biotech and Rongchang Biotech, indicating strong global competitiveness for Chinese innovative drugs [2] - Major companies are increasingly investing in the small nucleic acid field, with significant acquisitions and clinical approvals. For instance, China National Pharmaceutical Group acquired Hangzhou Hejiya Biopharmaceutical for 1.2 billion RMB, while international firms like Novartis and GSK are also advancing in this area [3] - The GLP-1 market is expected to grow despite new pricing systems, with ongoing collaborations and new product launches anticipated in 2026. The market for GLP-1 drugs is projected to remain robust due to the large patient population for weight loss and diabetes [4] - The oral autoimmune drug market is gaining attention, with promising results from Takeda's new TYK2 inhibitor for psoriasis. Other domestic companies are also advancing in this space, exploring new targets for oral small molecules [5] - The brain-computer interface sector is poised for industrialization, with companies like Neuralink set to produce devices in 2026. Domestic advancements and regulatory support are enhancing the potential for this technology in medical applications [6] - The ZAP-X radiation therapy device is expected to capture a significant market share in China, with rapid growth projected in non-invasive tumor radiation treatment, driven by increasing clinical recognition and adoption [8] Summary by Sections Industry Trends - The pharmaceutical sector is witnessing a resurgence in interest towards innovative drugs, with a notable increase in the innovative drug index by 8.97% since early January 2026, outperforming the CSI 300 index by 6.77 percentage points [2] Company Recommendations - Recommended companies include: - **Yuekang Pharmaceutical** and **Sunshine Nuohua** in the small nucleic acid space - **Yahong Pharmaceutical** and **Yifang Biotechnology** in the autoimmune sector - **Zhongsheng Pharmaceutical** in the GLP-1 market - **Baiyang Pharmaceutical** for ZAP-X radiation therapy - **Meihao Medical** for brain-computer interface technology [10] Market Opportunities - The non-invasive tumor radiation treatment market is projected to grow from 27.2 billion RMB in 2018 to 59.4 billion RMB by 2024, with a compound annual growth rate of 13.9% [8]

证券日报网讯 1月15日，百洋医药发布公告称，公司2026年第一次临时股东会审议通过《关于与专业投 资机构共同投资暨关联交易的议案》《关于2025年度关联交易确认及2026年度日常关联交易预计的议 案》。 （文章来源：证券日报） ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2026-002 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.召开时间： （1）现场会议召开时间：2026年1月15日（星期四）14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026年1月15日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网 投票系统投票的具体时间为2026年1月15日9:15至15:00的任意时间。 2.召开地点：山东省青岛市市北区桐柏路88号1号楼青岛百洋医药股份有限 公司会议室 3.召开方式：本次股东会采用现场表决与网络投票相结合的方式召开 4.召集人：董事会 5.主持人：董事长付钢 ...

北京市天元律师事务所 关于青岛百洋医药股份有限公司 2026 年第一次临时股东会的 法律意见 京天股字（2026）第 014 号 致：青岛百洋医药股份有限公司 青岛百洋医药股份有限公司（以下简称"公司"）2026 年第一次临时股东会（以 下简称"本次股东会"）采取现场投票与网络投票相结合的方式召开，其中现场会 议于 2026 年 1 月 15 日 14:30 在山东省青岛市市北区桐柏路 88 号 1 号楼青岛百洋 医药股份有限公司会议室召开。北京市天元律师事务所（以下简称"本所"）接受 公司聘任，指派本所律师出席本次股东会并进行见证，并根据《中华人民共和国 公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司股东会规则（2025 修订）》（以下简称"《股东会规则》"）以及 《青岛百洋医药股份有限公司章程》（以下简称"《公司章程》"）等有关规定，就 本次股东会的召集、召开程序、出席现场会议人员的资格、召集人资格、会议表 决程序及表决结果等事项出具本法律意见。 为出具本法律意见，本所律师审查了《青岛百洋医药股份有限公司第四届董 事会第四次会议决议公告》《青岛百洋医药 ...

Core Viewpoint - Baiyang Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.01% and a current price of 25.31 CNY per share, reflecting a total market capitalization of 13.304 billion CNY [1] Group 1: Stock Performance - Since the beginning of the year, Baiyang Pharmaceutical's stock price has increased by 7.25%, with a 3.86% rise over the last five trading days and a 12.44% increase over the last 20 days, while it has decreased by 1.86% over the last 60 days [1] - The trading volume reached 206 million CNY, with a turnover rate of 1.52% [1] Group 2: Financial Performance - For the period from January to September 2025, Baiyang Pharmaceutical reported a revenue of 5.627 billion CNY, representing a year-on-year decrease of 8.41%, and a net profit attributable to shareholders of 476 million CNY, down 25.67% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 1.551 billion CNY, with 1.201 billion CNY distributed over the last three years [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Baiyang Pharmaceutical is 11,100, a decrease of 40.83% from the previous period, while the average circulating shares per person increased by 68.99% to 47,194 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the newest shareholder, holding 2.9097 million shares [3]

Core Insights - The brain-computer interface (BCI) industry in China is experiencing significant advancements, with clinical results emerging for high-level paraplegics and substantial funding rounds, including a recent 2 billion yuan investment in a non-invasive unicorn company, Strong Brain Technology, marking the second-largest funding record globally in this field [1][2] - The industry is poised for rapid commercialization, driven by technological breakthroughs, capital influx, and supportive policies, as it transitions from cutting-edge technology to practical applications in daily life [1][5] Technological Breakthroughs - Recent advancements in BCI technology include successful clinical trials for invasive systems, enabling high-level paraplegics to control smart wheelchairs and robotic dogs [2][3] - Companies like JieTi Medical and Chip Intelligence have made significant progress, with JieTi completing trials for its invasive BCI system and Chip Intelligence's semi-invasive product achieving human implantation [2][3] - The first clinical trial of a fully implanted, wireless BCI product by Brain Tiger Technology has shown promising results, allowing an 8-year paraplegic patient to achieve thought control just five days post-surgery [2][3] Policy and Capital Support - The BCI sector benefits from comprehensive policy support, including its designation as one of the six future industries in the 14th Five-Year Plan, which elevates it to a national strategic priority [5][6] - Recent initiatives by the Sichuan provincial medical insurance bureau have established pricing for 82 neuro-related medical services, including BCI applications, facilitating clinical adoption [5][6] - The establishment of industry standards by the National Medical Products Administration is expected to lower costs and risks associated with technology development and clinical application [6] Industry Collaboration and Investment - Companies like Baiyang Pharmaceutical are actively collaborating with academic institutions to explore the integration of BCI with artificial intelligence, aiming for innovative clinical solutions [7] - Other listed companies are also engaging in the BCI space through material supply and equipment development, indicating a strong interest from institutional investors [7] Future Development and Challenges - The BCI industry is anticipated to move towards standardization and scalability, with initial industry standards expected to be established by 2027-2028 [8] - Potential constraints include the pace of chip design and production, as well as the need for ethical regulations regarding personal brain data [8] - Despite these challenges, the domestic BCI industry holds significant advantages, including strong policy support, a vast clinical resource base, and a comprehensive supply chain [8] Investment Opportunities - The BCI sector presents a dual investment opportunity in both medical and technological domains, with short-term focus on disease treatment and long-term potential for enhancing human capabilities through integration with AI and robotics [9] - The industry is positioned to cultivate leading global BCI companies, fostering a capital-innovation synergy between primary and secondary markets [9]

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]

Core Viewpoint - Enhertu (DS-8201) has evolved into a "complete entity" with the recent approval for first-line therapy in HER2+ breast cancer, marking significant progress from its initial approval as a third-line therapy in December 2019 to its current status [1][2] Group 1: Enhertu's Progression - Enhertu's journey includes approvals for HER2+ breast cancer in third-line therapy (December 2019), second-line therapy (January 2021), and now first-line therapy [2] - The first-line therapy approval is in combination with pertuzumab, with expectations for single-agent approval in the future [2] Group 2: Competitive Landscape - The HER2 ADC breast cancer market is approaching a critical phase, with companies like Rongchang Biopharma, Kelun-Biotech, and BaiLi Tianheng adopting various strategies to compete [3][6] - Rongchang Biopharma has focused on differentiated strategies, avoiding direct competition in breast cancer and targeting unmet clinical needs in other indications like gastric cancer [4][6] - Kelun-Biotech has actively pursued HER2+ breast cancer, achieving approval for its product A166 as the first domestic ADC for second-line therapy, leveraging a strategy of gradual advancement [7][9] Group 3: Strategic Approaches - BaiLi Tianheng aims to create a competitive product against Enhertu, with its T-Bren ADC targeting both HER2+ breast cancer and non-small cell lung cancer (NSCLC) [11][14] - HengRui Medicine adopts a multi-cancer strategy, focusing on various indications beyond breast cancer, with its SHR-A1811 ADC already approved for HER2-mutated NSCLC [16][17] Group 4: Differentiated Strategies - Lepu Biopharma's strategy centers on combining its ADC with PD-1 therapies, positioning its products as complementary rather than direct competitors [18][20] - In contrast, YingEn Biopharma has established a global strategy, securing a partnership with BioNTech for its DB-1303 ADC, focusing on unmet needs in endometrial cancer [22][24] Group 5: Future Outlook - The competitive landscape in the HER2 ADC market is intensifying, with companies employing diverse strategies to carve out their niches [26] - The future success in this sector may hinge on the depth of differentiated strategies and the ability to commercialize effectively, rather than solely on product efficacy [26]

Group 1 - The core viewpoint of the news is that Baiyang Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.04% and a total market value of 12.883 billion yuan [1] - As of January 12, Baiyang Pharmaceutical's stock price is 24.51 yuan per share, with a trading volume of 27.9698 million yuan and a turnover rate of 0.22% [1] - The company has seen a year-to-date stock price increase of 3.86%, but a decline of 2.85% over the last five trading days [1] Group 2 - Baiyang Pharmaceutical reported a revenue of 5.627 billion yuan for the period from January to September 2025, representing a year-on-year decrease of 8.41% [2] - The net profit attributable to the parent company for the same period was 476 million yuan, down 25.67% year-on-year [2] - The company has distributed a total of 1.551 billion yuan in dividends since its A-share listing, with 1.201 billion yuan distributed in the last three years [3] Group 3 - As of September 30, 2025, the number of shareholders in Baiyang Pharmaceutical decreased by 40.83% to 11,100 [2] - The average number of circulating shares per person increased by 68.99% to 47,194 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is a new entrant, holding 2.9097 million shares [3]